Loading
Life sciences · Journal article
Next Nanotechnology · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cervical cancer (CC) remains a significant global health burden, ranking as the fourth most common cancer among women worldwide. Persistent infection with high-risk human papillomavirus (HPV) is the primary etiological factor, although tumor progression is also influenced by genetic alterations, immune dysregulation, and changes within the tumor microenvironment. Current therapeutic approaches, including surgery, radiotherapy, chemotherapy, and targeted treatment, often lack sufficient tumor specificity, resulting in damage to healthy tissues, treatment-related toxicity, and limited therapeutic efficacy. Nanomedicine has emerged as a promising strategy to address these limitations. Exosomes and lipid nanoparticles (LNPs) are biocompatible and, in many cases, biodegradable delivery systems capable of transporting anticancer drugs, nucleic acids, and combination therapies. Their ability to enhance tumor accumulation, protect therapeutic cargo, and reduce systemic exposure may improve treatment outcomes. Furthermore, surface modification with lipid-like moieties, antibodies, peptides, or other targeting ligands can promote selective uptake by CC cells and stromal components of the tumor microenvironment. These nanocarriers may also help overcome drug resistance and facilitate synergistic therapeutic combinations. This review summarizes the pathophysiology of CC and examines recent advances in exosome- and LNP-based therapeutic platforms, including clinically approved nanoparticle formulations and emerging translational studies. We discuss their advantages, limitations, safety considerations, and future prospects for precision treatment, with the goal of improving efficacy, reducing adverse effects, and enhancing patient survival and quality of life.